• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
ACE inhibitors and the risk of lung cancer-is there causality?血管紧张素转换酶抑制剂与肺癌风险——存在因果关系吗？
Br J Cancer. 2023 Sep;129(4):570-571. doi: 10.1038/s41416-023-02346-3. Epub 2023 Jul 4.
2
Modest Association of Long-Term ACE Inhibitor Treatment With Lung Cancer: The Promise and Pitfalls of Epidemiological Drug-Safety Analyses.长期使用 ACEI 类药物与肺癌的适度关联：流行病学药物安全性分析的前景与陷阱。
J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):371-374. doi: 10.1177/10742484211000521. Epub 2021 Mar 25.
3
Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea.血管紧张素转换酶抑制剂与韩国常见数据模型人群肺癌发病率的关系。
Sci Rep. 2021 Sep 17;11(1):18576. doi: 10.1038/s41598-021-97989-8.
4
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.血管紧张素转化酶抑制剂与肺癌风险：基于人群的队列研究。
BMJ. 2018 Oct 24;363:k4209. doi: 10.1136/bmj.k4209.
5
Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer: A Nationwide Nested Case-Control Study.血管紧张素转换酶抑制剂的使用与肺癌风险：一项全国性巢式病例对照研究。
Circ Cardiovasc Qual Outcomes. 2021 Jan;14(1):e006687. doi: 10.1161/CIRCOUTCOMES.120.006687. Epub 2021 Jan 13.
6
Long-term Use of Angiotensin-converting Enzyme Inhibitors Increases Substance P Levels, Which is Involved in the Risk of Lung Cancer.长期使用血管紧张素转换酶抑制剂会增加P物质水平，而P物质与肺癌风险有关。
Arch Bronconeumol. 2023 Dec;59(12):848-849. doi: 10.1016/j.arbres.2023.09.017. Epub 2023 Oct 11.
7
Risk of lung cancer and renin-angiotensin blockade: a concise review.肺癌与肾素-血管紧张素阻断的风险：简要综述。
J Cancer Res Clin Oncol. 2021 Jan;147(1):195-204. doi: 10.1007/s00432-020-03445-x. Epub 2020 Nov 24.
8
[ACE inhibitors and the risk of lung cancer. What doctors should consider].[血管紧张素转换酶抑制剂与肺癌风险。医生应考虑的因素]
MMW Fortschr Med. 2021 Feb;163(3):66-67. doi: 10.1007/s15006-021-9603-6.
9
Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂起始治疗者咳嗽的诊断评估比较
Pharmacoepidemiol Drug Saf. 2016 May;25(5):512-20. doi: 10.1002/pds.3977. Epub 2016 Feb 10.
10
Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.孕早期接触血管紧张素转换酶抑制剂后先天性畸形增加的临床意义。
J Cardiovasc Nurs. 2008 Jan-Feb;23(1):20-4. doi: 10.1097/01.JCN.0000305052.73376.de.

本文引用的文献

1
Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis.血管紧张素转化酶抑制剂与肺癌风险的关系：系统评价和荟萃分析。
Br J Cancer. 2023 Jan;128(2):168-176. doi: 10.1038/s41416-022-02029-5. Epub 2022 Nov 17.
2
Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials.血管紧张素受体阻滞剂的癌症风险随累积暴露量增加而增加：随机试验的荟萃回归分析。
PLoS One. 2022 Mar 2;17(3):e0263461. doi: 10.1371/journal.pone.0263461. eCollection 2022.
3
The Effect of Local Renin Angiotensin System in the Common Types of Cancer.局部肾素-血管紧张素系统在常见癌症类型中的作用。
Front Endocrinol (Lausanne). 2021 Sep 3;12:736361. doi: 10.3389/fendo.2021.736361. eCollection 2021.
4
Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与肺癌之间的关联。
South Med J. 2021 Sep;114(9):607-613. doi: 10.14423/SMJ.0000000000001293.
5
Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials.肾素血管紧张素阻滞剂与心脏保护：从基础到临床试验。
Am J Hypertens. 2022 Apr 2;35(4):293-302. doi: 10.1093/ajh/hpab108.
6
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.抗高血压治疗与癌症风险：一项个体参与者数据荟萃分析。
Lancet Oncol. 2021 Apr;22(4):558-570. doi: 10.1016/S1470-2045(21)00033-4.
7
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.基于真实世界证据的非随机研究模拟随机对照试验：RCT DUPLICATE 计划的初步结果。
Circulation. 2021 Mar 9;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17.
8
Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls.血管紧张素受体阻滞剂与癌症风险：临床试验和近期药物召回的启示。
Curr Hypertens Rep. 2020 Feb 29;22(3):20. doi: 10.1007/s11906-020-1021-0.
9
Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox.血管紧张素受体阻滞剂不能降低心肌梗死风险、心血管死亡风险或全因死亡率：血管紧张素受体阻滞剂 - 心肌梗死悖论的进一步证据。
Circulation. 2017 May 30;135(22):2088-2090. doi: 10.1161/CIRCULATIONAHA.117.026112.
10
Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.血管紧张素转化酶抑制剂对癌症风险影响的随机对照试验的荟萃分析。
Am J Cardiol. 2011 Jul 15;108(2):294-301. doi: 10.1016/j.amjcard.2011.03.038. Epub 2011 May 19.

ACE inhibitors and the risk of lung cancer-is there causality?

作者信息

Strauss Martin H, Sipahi Ilke, Hall Alistair S

机构信息

University of Toronto, North York General Hospital, Toronto, ON, Canada.

Leeds School of Medicine, University of Leeds, Leeds, UK.

出版信息

Br J Cancer. 2023 Sep;129(4):570-571. doi: 10.1038/s41416-023-02346-3. Epub 2023 Jul 4.

DOI:10.1038/s41416-023-02346-3
PMID:37400679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10421851/
Abstract
摘要